A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.

Pathobiology : journal of immunopathology, molecular and cellular biology Pub Date : 2022-01-01 Epub Date: 2022-01-14 DOI:10.1159/000521253

Bruna Minniti Mançano, Mariana Bisarro Dos Reis, Daniel Antunes Moreno, Flávia Escremim de Paula, Carlos Roberto de Almeida Junior, Carlos Eduardo Bezerra Cavalcante, Maicon Fernando Zanon, Iara Viana Vidigal Santana, Marcus de Medeiros Matsushita, Rui Manuel Reis

{"title":"A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.","authors":"Bruna Minniti Mançano, Mariana Bisarro Dos Reis, Daniel Antunes Moreno, Flávia Escremim de Paula, Carlos Roberto de Almeida Junior, Carlos Eduardo Bezerra Cavalcante, Maicon Fernando Zanon, Iara Viana Vidigal Santana, Marcus de Medeiros Matsushita, Rui Manuel Reis","doi":"10.1159/000521253","DOIUrl":null,"url":null,"abstract":"<p><p>Herein, we present a rare case of a nine-month-old boy diagnosed with infant-type hemispheric glioma (gliosarcoma subtype) at the left frontal lobe. Following subtotal resection, the patient started chemotherapy with the BABY POG protocol. We describe the clinical diagnosis, histological characteristics, radiological features, molecular aspects, and management of this tumor. A comprehensive molecular analysis on the tumor tissue showed a TPR-NTRK1 gene fusion. The patient was treated with a TRK inhibitor, larotrectinib, and exhibited a stable disease with residual lesion following 8 months of target therapy. The present study is the first report of an infantile gliosarcoma harboring NTRK1 rearrangement treated with larotrectinib.</p>","PeriodicalId":244631,"journal":{"name":"Pathobiology : journal of immunopathology, molecular and cellular biology","volume":" ","pages":"178-185"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathobiology : journal of immunopathology, molecular and cellular biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000521253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 6

Abstract

Herein, we present a rare case of a nine-month-old boy diagnosed with infant-type hemispheric glioma (gliosarcoma subtype) at the left frontal lobe. Following subtotal resection, the patient started chemotherapy with the BABY POG protocol. We describe the clinical diagnosis, histological characteristics, radiological features, molecular aspects, and management of this tumor. A comprehensive molecular analysis on the tumor tissue showed a TPR-NTRK1 gene fusion. The patient was treated with a TRK inhibitor, larotrectinib, and exhibited a stable disease with residual lesion following 8 months of target therapy. The present study is the first report of an infantile gliosarcoma harboring NTRK1 rearrangement treated with larotrectinib.

查看原文本刊更多论文

larorectinib治疗TPR-NTRK1融合的婴儿型半球胶质瘤(胶质瘤亚型)的独特病例报告

在此，我们报告一个罕见的病例，九个月大的男孩被诊断为左额叶婴儿型半球胶质瘤(胶质瘤亚型)。次全切除后，患者开始采用BABY POG方案进行化疗。我们描述临床诊断，组织学特征，放射学特征，分子方面，和管理这个肿瘤。对肿瘤组织的综合分子分析显示TPR-NTRK1基因融合。患者接受TRK抑制剂larorectinib治疗，经过8个月的靶向治疗，病情稳定，病灶残留。本研究是第一个用larotrectinib治疗含有NTRK1重排的婴儿胶质瘤的报道。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathobiology : journal of immunopathology, molecular and cellular biology

自引率

0.00%

发文量